{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:15:29Z","timestamp":1790716529538,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001323","name":"Poliomyelitis Research Foundation","doi-asserted-by":"publisher","award":["22\/82"],"award-info":[{"award-number":["22\/82"]}],"id":[{"id":"10.13039\/501100001323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["PMDS2205067384"],"award-info":[{"award-number":["PMDS2205067384"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["84177"],"award-info":[{"award-number":["84177"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-025-00941-4","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T08:44:09Z","timestamp":1749545049000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["T-cell responses induced by SARS-CoV-2 index-virus nanoparticle protein vaccine to the ancestral and omicron variants 6 months following primary vaccination"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8705-5423","authenticated-orcid":false,"given":"William C.","family":"McMahon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Kwatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta C.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alane","family":"Izu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthonet L.","family":"Koen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Greffrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Shalekoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline T.","family":"Tiemessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Shinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chijioke","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7629-0636","authenticated-orcid":false,"given":"Shabir A.","family":"Madhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"941_CR1","doi-asserted-by":"publisher","first-page":"105321","DOI":"10.1016\/j.jcv.2022.105321","volume":"157","author":"F Hielscher","year":"2022","unstructured":"Hielscher, F. et al. NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens. J. Clin. Virol. 157, 105321 (2022).","journal-title":"J. Clin. Virol."},{"key":"941_CR2","doi-asserted-by":"publisher","first-page":"3930","DOI":"10.1016\/j.vaccine.2023.05.016","volume":"41","author":"K Smith","year":"2023","unstructured":"Smith, K. et al. Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled clinical trials. Vaccine 41, 3930\u20133936 (2023).","journal-title":"Vaccine"},{"key":"941_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20653-8","volume":"12","author":"JH Tian","year":"2021","unstructured":"Tian, J. H. et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat. Commun. 12, 372 (2021).","journal-title":"Nat. Commun."},{"key":"941_CR4","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/j.vaccine.2016.02.033","volume":"34","author":"KL Bengtsson","year":"2016","unstructured":"Bengtsson, K. L. et al. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola\/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. Vaccine 34, 1927\u20131935 (2016).","journal-title":"Vaccine"},{"key":"941_CR5","doi-asserted-by":"publisher","first-page":"2189885","DOI":"10.1080\/21645515.2023.2189885","volume":"19","author":"L Stertman","year":"2023","unstructured":"Stertman, L. et al. The matrix-M adjuvant: a critical component of vaccines for the 21(st) century. Hum. Vaccin. Immunother. 19, 2189885 (2023).","journal-title":"Hum. Vaccin. Immunother."},{"key":"941_CR6","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","volume":"383","author":"C Keech","year":"2020","unstructured":"Keech, C. et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N. Engl. J. Med. 383, 2320\u20132332 (2020).","journal-title":"N. Engl. J. Med."},{"key":"941_CR7","doi-asserted-by":"publisher","first-page":"e1003769","DOI":"10.1371\/journal.pmed.1003769","volume":"18","author":"N Formica","year":"2021","unstructured":"Formica, N. et al. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized placebo-controlled trial. PLoS Med. 18, e1003769 (2021).","journal-title":"PLoS Med."},{"key":"941_CR8","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","volume":"385","author":"PT Heath","year":"2021","unstructured":"Heath, P. T. et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N. Engl. J. Med. 385, 1172\u20131183 (2021).","journal-title":"N. Engl. J. Med."},{"key":"941_CR9","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1056\/NEJMoa2103055","volume":"384","author":"V Shinde","year":"2021","unstructured":"Shinde, V. et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. N. Engl. J. Med. 384, 1899\u20131909 (2021).","journal-title":"N. Engl. J. Med."},{"key":"941_CR10","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/S1473-3099(22)00420-0","volume":"22","author":"RM Mallory","year":"2022","unstructured":"Mallory, R. M. et al. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. Lancet Infect. Dis. 22, 1565\u20131576 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"941_CR11","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1016\/S2352-3018(22)00041-8","volume":"9","author":"SA Madhi","year":"2022","unstructured":"Madhi, S. A. et al. Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A\/2B trial. Lancet HIV 9, e309\u2013e322 (2022).","journal-title":"Lancet HIV"},{"key":"941_CR12","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa2116185","volume":"386","author":"LM Dunkle","year":"2022","unstructured":"Dunkle, L. M. et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N. Engl. J. Med. 386, 531\u2013543 (2022).","journal-title":"N. Engl. J. Med."},{"key":"941_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S2213-2600(21)00409-4","volume":"10","author":"S Toback","year":"2022","unstructured":"Toback, S. et al. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respir. Med 10, 167\u2013179 (2022).","journal-title":"Lancet Respir. Med"},{"key":"941_CR14","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.1016\/j.vaccine.2023.05.051","volume":"41","author":"K Alves","year":"2023","unstructured":"Alves, K. et al. Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373. Vaccine 41, 4280\u20134286 (2023).","journal-title":"Vaccine"},{"key":"941_CR15","doi-asserted-by":"publisher","first-page":"e239135","DOI":"10.1001\/jamanetworkopen.2023.9135","volume":"6","author":"G Anez","year":"2023","unstructured":"Anez, G. et al. Safety, immunogenicity, and efficacy of the NVX-CoV2373 COVID-19 vaccine in adolescents: a randomized clinical trial. JAMA Netw. Open 6, e239135 (2023).","journal-title":"JAMA Netw. Open"},{"key":"941_CR16","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/cid\/ciac803","volume":"76","author":"PT Heath","year":"2023","unstructured":"Heath, P. T. et al. Safety and efficacy of the NVX-CoV2373 coronavirus disease 2019 vaccine at completion of the placebo-controlled phase of a randomized controlled trial. Clin. Infect. Dis. 76, 398\u2013407 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"941_CR17","doi-asserted-by":"publisher","first-page":"5965","DOI":"10.1016\/j.vaccine.2023.07.056","volume":"41","author":"F Raiser","year":"2023","unstructured":"Raiser, F. et al. Immunogenicity and safety of NVX-CoV2373 as a booster: a phase 3 randomized clinical trial in adults. Vaccine 41, 5965\u20135973 (2023).","journal-title":"Vaccine"},{"key":"941_CR18","doi-asserted-by":"publisher","first-page":"106285","DOI":"10.1016\/j.jinf.2024.106285","volume":"89","author":"C Bennett","year":"2024","unstructured":"Bennett, C. et al. Immunogenicity and safety of SARS-CoV-2 recombinant spike protein vaccine in South African people living with and without HIV-1 infection: a phase 2 randomised trial. J. Infect. 89, 106285 (2024).","journal-title":"J. Infect."},{"key":"941_CR19","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","volume":"184","author":"A Sette","year":"2021","unstructured":"Sette, A. & Crotty, S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 184, 861\u2013880 (2021).","journal-title":"Cell"},{"key":"941_CR20","doi-asserted-by":"publisher","unstructured":"Zhou, P. Protein vaccine NVX-CoV2373 elicits functional T cell immunity. J. Clin. Invest. 132, https:\/\/doi.org\/10.1172\/JCI163614 (2022).","DOI":"10.1172\/JCI163614"},{"key":"941_CR21","doi-asserted-by":"crossref","unstructured":"Rydyznski Moderbacher, C. et al. NVX-CoV2373 vaccination induces functional SARS-CoV-2-specific CD4+ and CD8+ T cell responses. J. Clin. Invest. 132, e163614 (2022).","DOI":"10.1172\/JCI160898"},{"key":"941_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-27698-x","volume":"13","author":"JN Bhiman","year":"2023","unstructured":"Bhiman, J. N. et al. Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages. Sci. Rep. 13, 1222 (2023).","journal-title":"Sci. Rep."},{"key":"941_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ijid.2022.11.022","volume":"126","author":"S Kanokudom","year":"2023","unstructured":"Kanokudom, S. et al. Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (Covovax(TM)) after homologous and heterologous two-dose regimens. Int. J. Infect. Dis. 126, 64\u201372 (2023).","journal-title":"Int. J. Infect. Dis."},{"key":"941_CR24","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","volume":"398","author":"APS Munro","year":"2021","unstructured":"Munro, A. P. S. et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet 398, 2258\u20132276 (2021).","journal-title":"Lancet"},{"key":"941_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-43578-w","volume":"13","author":"PS Kulkarni","year":"2023","unstructured":"Kulkarni, P. S. et al. A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults. Sci. Rep. 13, 16579 (2023).","journal-title":"Sci. Rep."},{"key":"941_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jinf.2023.04.012","volume":"87","author":"X Liu","year":"2023","unstructured":"Liu, X. et al. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial. J. Infect. 87, 18\u201326 (2023).","journal-title":"J. Infect."},{"key":"941_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00693-z","volume":"8","author":"KE Lyke","year":"2023","unstructured":"Lyke, K. E. et al. Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants. NPJ Vaccines 8, 98 (2023).","journal-title":"NPJ Vaccines"},{"key":"941_CR28","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1080\/14760584.2023.2232020","volume":"22","author":"AM Marchese","year":"2023","unstructured":"Marchese, A. M. et al. Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines. Expert Rev. Vaccines 22, 620\u2013628 (2023).","journal-title":"Expert Rev. Vaccines"},{"key":"941_CR29","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/j.vaccine.2024.02.037","volume":"42","author":"S Toback","year":"2024","unstructured":"Toback, S. et al. Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine. Vaccine 42, 1777\u20131784 (2024).","journal-title":"Vaccine"},{"key":"941_CR30","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1093\/infdis\/jiad163","volume":"228","author":"L Fries","year":"2023","unstructured":"Fries, L. et al. Strong CD4+ T-Cell responses to ancestral and variant spike proteins are established by NVX-CoV2373 severe acute respiratory syndrome coronavirus 2 primary vaccination. J. Infect. Dis. 228, 734\u2013741 (2023).","journal-title":"J. Infect. Dis."},{"key":"941_CR31","doi-asserted-by":"crossref","unstructured":"Madhi, S. A. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebocontrolled, phase 1B\/2A trial. Lancet HIV 8, e568\u2013e580 (2021).","DOI":"10.1016\/S2352-3018(21)00157-0"},{"key":"941_CR32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99\u2013111 (2021).","journal-title":"Lancet"},{"key":"941_CR33","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3390\/cells1030313","volume":"1","author":"H Ramachandran","year":"2012","unstructured":"Ramachandran, H. et al. Optimal thawing of cryopreserved peripheral blood mononuclear cells for use in high-throughput human immune monitoring studies. Cells 1, 313\u2013324 (2012).","journal-title":"Cells"},{"key":"941_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-70725-8","volume":"14","author":"WC McMahon","year":"2024","unstructured":"McMahon, W. C. et al. T-cell responses to ancestral SARS-CoV-2 and Omicron variant among unvaccinated pregnant and postpartum women living with and without HIV in South Africa. Sci. Rep. 14, 20348 (2024).","journal-title":"Sci. Rep."},{"key":"941_CR35","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/cyto.a.21015","volume":"79","author":"M Roederer","year":"2011","unstructured":"Roederer, M., Nozzi, J. L. & Nason, M. C. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytom. A 79, 167\u2013174 (2011).","journal-title":"Cytom. A"},{"key":"941_CR36","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/nri3152","volume":"12","author":"SL Swain","year":"2012","unstructured":"Swain, S. L., McKinstry, K. K. & Strutt, T. M. Expanding roles for CD4(+) T cells in immunity to viruses. Nat. Rev. Immunol. 12, 136\u2013148 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"941_CR37","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1586\/erv.11.25","volume":"10","author":"K Lovgren Bengtsson","year":"2011","unstructured":"Lovgren Bengtsson, K., Morein, B. & Osterhaus, A. D. ISCOM technology-based Matrix M adjuvant: success in future vaccines relies on formulation. Expert Rev. Vaccines 10, 401\u2013403 (2011).","journal-title":"Expert Rev. Vaccines"},{"key":"941_CR38","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s12026-018-8991-x","volume":"66","author":"SE Magnusson","year":"2018","unstructured":"Magnusson, S. E. et al. Matrix-M adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice. Immunol. Res. 66, 224\u2013233 (2018).","journal-title":"Immunol. Res."},{"key":"941_CR39","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev-immunol-031210-101400","volume":"29","author":"S Crotty","year":"2011","unstructured":"Crotty, S. Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 29, 621\u2013663 (2011).","journal-title":"Annu. Rev. Immunol."},{"key":"941_CR40","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1146\/annurev-immunol-041015-055605","volume":"34","author":"CG Vinuesa","year":"2016","unstructured":"Vinuesa, C. G., Linterman, M. A., Yu, D. & MacLennan, I. C. Follicular helper T Cells. Annu. Rev. Immunol. 34, 335\u2013368 (2016).","journal-title":"Annu. Rev. Immunol."},{"key":"941_CR41","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1038\/cti.2017.17","volume":"6","author":"CS Ma","year":"2017","unstructured":"Ma, C. S. & Deenick, E. K. The circulating life of a memory T-follicular helper cell. Clin. Transl. Immunol. 6, e141 (2017).","journal-title":"Clin. Transl. Immunol."},{"key":"941_CR42","doi-asserted-by":"crossref","unstructured":"Beura, L. K., Jameson, S. C. & Masopust, D. Is a human CD8 T-Cell vaccine possible, and if so, what would it take? CD8 T-cell vaccines: to B or not to B? Cold Spring Harb. Perspect. Biol. 10, e028910 (2018).","DOI":"10.1101\/cshperspect.a028910"},{"key":"941_CR43","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1016\/j.cell.2022.05.022","volume":"185","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z. et al. Humoral and cellular immune memory to four COVID-19 vaccines. Cell 185, 2434\u20132451.e2417 (2022).","journal-title":"Cell"},{"key":"941_CR44","doi-asserted-by":"publisher","first-page":"eadd3899","DOI":"10.1126\/sciimmunol.add3899","volume":"7","author":"Y Maringer","year":"2022","unstructured":"Maringer, Y. et al. Durable spike-specific T cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination. Sci. Immunol. 7, eadd3899 (2022).","journal-title":"Sci. Immunol."},{"key":"941_CR45","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1126\/science.abq0203","volume":"377","author":"JE Bowen","year":"2022","unstructured":"Bowen, J. E. et al. Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines. Science 377, 890\u2013894 (2022).","journal-title":"Science"},{"key":"941_CR46","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","volume":"608","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 608, 593\u2013602 (2022).","journal-title":"Nature"},{"key":"941_CR47","doi-asserted-by":"crossref","unstructured":"Lesmes-Rodr\u00edguez, L. C. et al. Previous exposure to common coronavirus HCoV-NL63 is associated with reduced COVID-19 severity in patients from Cape Town, South Africa. Front. Virol. 3, 1125448 (2023).","DOI":"10.3389\/fviro.2023.1125448"},{"key":"941_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45043-2","volume":"15","author":"RP Dos Santos Alves","year":"2024","unstructured":"Dos Santos Alves, R. P. et al. Human coronavirus OC43-elicited CD4(+) T cells protect against SARS-CoV-2 in HLA transgenic mice. Nat. Commun. 15, 787 (2024).","journal-title":"Nat. Commun."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00941-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00941-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00941-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T10:29:36Z","timestamp":1751624976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00941-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["941"],"URL":"https:\/\/doi.org\/10.1038\/s43856-025-00941-4","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]},"assertion":[{"value":"29 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: S.A.M., M.C.N. and G.K. report receiving grant support, paid to their institution, from Novavax and the Bill & Melinda Gates Foundation; V.S. and C.B. report being employed by and owning shares in Novavax and contributed to the interpretation of the study\u2019s results. No competing interests were declared for the remaining authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"220"}}